Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Belgium
10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Mechelen, Mons
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Brussels, Ghent, Herentals, Roeselare, Verviers
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 2. fázisTaking peopleA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Where
- Brugge, La Louvière, Leuven, Mechelen, Roeselare, Sint-Lambrechts-Woluwe, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 594 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Gent
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisNot yet taking people in BelgiumHOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
- Where
- Brasschaat, Brugge, Gent, Leuven
- Életkor
- 65 év and over
- People
- 276 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524230-25-00 · EU 2025-524230-25-00 - 1. fázisTaking peopleA Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Where
- Brussels, Edegem, Ghent, Leuven
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07195916 · EU 2025-523130-11-00 - 2. fázisTaking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Anderlecht, Leuven
- Életkor
- 18 év to 70 év
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - No phaseTaking peopleReal-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
- Where
- Boussu, Brasschaat, Charleroi, Genk, Jette, La Louvière, Liège, Ostend, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AbbVie
See details and how to joinNCT06830759 - 1/2. fázisTaking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Edegem, Hasselt, Leuven
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394 - 1/2. fázisTaking peoplePhase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
- Where
- Antwerp
- Életkor
- 18 év to 64 év
- People
- 37 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00